Leukemia/MDS Clinical Trials

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakp...

Diagnosis: Leukemia/MDS

Phase: 3

Protocol Number: 15-709

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS. The safety ...

Diagnosis: Leukemia/MDS

Phase: 2

Protocol Number: 15-180

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In this research study we will start by looking for the highest dose of pyrimethamine that can be given safely to CLL patients without severe or unmanageable side effects. This dose will then be us...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 09-421

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS

This 2-stage, open-label study will evaluate safety and pharmacokinetics of ASTX727, as well as determine the dose for the study's second stage. In the second stage the selected dose will be co...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 14-195

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine. GO-203-2c targets ...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 14-222

SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

This is a non-randomized, open-label, multi center study. A cycle of therapy is 5 consecutive days every 21 days for 6 or more cycles. Stage I will consist of a brief run-in period in which patient...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 14-454

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

This is a non-randomized open label multi-center study. Patients who are in their first complete remission (CR) following induction therapy will be treated with SL-401, which will be administered a...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 15-456

A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral A-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)

This Phase 1b/2 study is an open-label, randomized, multicenter trial to evaluate the safety and efficacy of oral AG-120 + SC azacitidine and oral A-221 + Subcutaneous (SC) azacitidine in subjects ...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 16-057

SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

This is a non-randomized open label multi-center study. Patients with high-risk myeloproliferative neoplasms (systemic mastocytosis [SM], advanced symptomatic hypereosinoophic disorder [PED], myelo...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 16-149

Brentuximab Vedotin + Chemo for AML

This research study is a Phase I clinical trial. Phase I trials test the safety of an investigational drug or combination of drugs. These trials also try to define the appropriate dose of the inves...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 13-040

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

This research study is evaluating a combination of drugs considered standard treatment for children and young adults with acute lymphoblastic leukemia (ALL), in combination with a new drug called M...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 14-200

Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

This research study is evaluating drugs called bortezomib and lenalidomide as a possible treatment for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The purpose of this research s...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 14-213

A Dose Escalation and Cohort Expansion Study of RO6870810/TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

TEN-010 is a small molecule, bromodomain and extra-terminal domain (BET) bromodomain inhibitor. This study is designed to characterize the safety, tolerability, and pharmacokinetics of TEN-010 in p...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 14-505

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 15-283

MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin and cytarabi...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 15-276

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive disease.

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 16-215

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 16-426

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

This phase I trial studies the side effects and best dose of ipilimumab when given together with decitabine in treating patients with myelodysplastic syndrome or acute myeloid leukemia that has ret...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 17-718

Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies

This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of BLU-285, administered...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 15-559

Study of INCB053914 in Subjects With Advanced Malignancies

This is an open-label, dose-escalation study of the PIM kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 2 parts. Part 1 (dose escalation) will eva...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 15-576

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML induction and consolidation therapy. The study pl...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 15-527

A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia

This research study is evaluating the impact a collaborative palliative care and oncology team will have on the quality of life, symptoms, mood, and end of life outcomes of patients with acute myel...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 16-439

Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

This study will include a Phase 1 dose-finding portion (Cohorts A and B) and a four-arm expansion portion. The primary objectives of the study are to determine the maximum tolerated dose (MTD) and ...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 16-326

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

The primary objective for this study is to assess the safety and tolerability as well as preliminary efficacy of venetoclax in combination with cobimetinib, and venetoclax in combination with idasa...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 16-184

A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 16-271

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Intravenous BI 836826 in combination with ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia (CLL) patients who have been pre-treated with at least one prior line of systemic therapy, an...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 16-278

Study of Regorafenib in Patients With Advanced Myeloid Malignancies

This research study is studying a drug as a possible treatment for advanced myeloid malignancies including AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MPN (myeloproliferative n...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 16-464

DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved i...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 16-593

SL-401 in Combination With Azacitidine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

This research study is studying a drug as a possible treatment for diagnosis of AML and high-risk MDS. The interventions involved in this study are: - SL-401 - Azacitidine

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 17-056

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

This study will evaluate the efficacy, safety, tolerability, and pharmacodynamics of entospletinib (GS-9973) when administered as monotherapy or in combination with chemotherapy in adults with acut...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 17-012